Key Points
- Director Louis Lange sold 44,619 shares of NewAmsterdam Pharma at an average price of $30.42 for a total of $1,357,309.98, cutting his ownership by 81.16% to 10,360 shares; the transaction was disclosed in an SEC filing.
- Shares traded at $29.61 (down $0.21) and the company reported a Q that missed estimates (EPS -$0.63) with very negative margins and minimal revenue, yet analysts maintain a consensus "Moderate Buy" with an average target of $47.10.
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) Director Louis Lange sold 44,619 shares of NewAmsterdam Pharma stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $30.42, for a total value of $1,357,309.98. Following the completion of the sale, the director owned 10,360 shares of the company's stock, valued at $315,151.20. The trade was a 81.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
NewAmsterdam Pharma Trading Down 0.7%
NASDAQ:NAMS traded down $0.21 during mid-day trading on Friday, reaching $29.61. The company's stock had a trading volume of 260,399 shares, compared to its average volume of 759,975. The stock has a market cap of $3.40 billion, a P/E ratio of -17.09 and a beta of 0.04. The firm's fifty day moving average price is $33.24 and its two-hundred day moving average price is $33.32. NewAmsterdam Pharma Company N.V. has a 12-month low of $14.06 and a 12-month high of $42.00.
NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its quarterly earnings results on Wednesday, February 18th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 26.67%. The company had revenue of $0.03 million for the quarter, compared to analysts' expectations of $0.92 million. Analysts predict that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.
Institutional Investors Weigh In On NewAmsterdam Pharma
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Farther Finance Advisors LLC raised its holdings in NewAmsterdam Pharma by 4,425.0% in the 4th quarter. Farther Finance Advisors LLC now owns 724 shares of the company's stock worth $25,000 after purchasing an additional 708 shares during the period. Mather Group LLC. bought a new stake in NewAmsterdam Pharma during the third quarter valued at about $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in NewAmsterdam Pharma in the third quarter worth about $30,000. Wells Fargo & Company MN raised its stake in shares of NewAmsterdam Pharma by 50.0% in the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company's stock worth $32,000 after buying an additional 300 shares during the period. Finally, Navalign LLC bought a new position in shares of NewAmsterdam Pharma in the fourth quarter worth about $46,000. 89.89% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of research firms have commented on NAMS. Stifel Nicolaus lifted their target price on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a "buy" rating in a research report on Tuesday, December 16th. The Goldman Sachs Group raised their price target on NewAmsterdam Pharma from $30.00 to $37.00 and gave the stock a "neutral" rating in a research note on Tuesday, December 2nd. Wall Street Zen lowered NewAmsterdam Pharma from a "hold" rating to a "sell" rating in a report on Saturday, February 21st. Royal Bank Of Canada upped their price objective on NewAmsterdam Pharma from $44.00 to $47.00 and gave the company an "outperform" rating in a research report on Wednesday, January 21st. Finally, Guggenheim increased their target price on NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a "buy" rating in a report on Thursday, February 19th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, NewAmsterdam Pharma currently has an average rating of "Moderate Buy" and a consensus target price of $47.10.
View Our Latest Stock Analysis on NAMS
About NewAmsterdam Pharma
(
Get Free Report)
NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.
The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
